Stevens Capital Management LP Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN

Stevens Capital Management LP bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 1,409 shares of the biopharmaceutical company’s stock, valued at approximately $792,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in REGN. CoreCap Advisors LLC increased its holdings in shares of Regeneron Pharmaceuticals by 9.2% in the third quarter. CoreCap Advisors LLC now owns 238 shares of the biopharmaceutical company’s stock valued at $134,000 after purchasing an additional 20 shares during the period. Strait & Sound Wealth Management LLC raised its position in Regeneron Pharmaceuticals by 3.5% during the 3rd quarter. Strait & Sound Wealth Management LLC now owns 628 shares of the biopharmaceutical company’s stock worth $353,000 after buying an additional 21 shares during the last quarter. Parkside Financial Bank & Trust lifted its stake in shares of Regeneron Pharmaceuticals by 14.8% in the 3rd quarter. Parkside Financial Bank & Trust now owns 163 shares of the biopharmaceutical company’s stock worth $92,000 after acquiring an additional 21 shares during the period. Independence Bank of Kentucky boosted its holdings in shares of Regeneron Pharmaceuticals by 7.7% in the third quarter. Independence Bank of Kentucky now owns 308 shares of the biopharmaceutical company’s stock valued at $173,000 after acquiring an additional 22 shares in the last quarter. Finally, Redwood Wealth Management Group LLC increased its stake in shares of Regeneron Pharmaceuticals by 4.8% during the second quarter. Redwood Wealth Management Group LLC now owns 506 shares of the biopharmaceutical company’s stock worth $266,000 after acquiring an additional 23 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Trading Down 0.3%

Shares of Regeneron Pharmaceuticals stock opened at $779.67 on Friday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $821.11. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39. The business has a 50 day moving average price of $768.98 and a 200 day moving average price of $673.84. The company has a market capitalization of $82.43 billion, a P/E ratio of 18.76, a P/E/G ratio of 2.09 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. The company had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $12.07 earnings per share. Sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 5th. Stockholders of record on Friday, February 20th will be given a $0.94 dividend. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.47%.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the sale, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. The trade was a 46.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $778.53, for a total value of $77,853.00. Following the completion of the transaction, the director owned 17,803 shares of the company’s stock, valued at $13,860,169.59. This trade represents a 0.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 3,636 shares of company stock valued at $2,862,920. Company insiders own 7.02% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. Citigroup boosted their target price on Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Truist Financial reduced their target price on Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating for the company in a report on Monday, February 2nd. BMO Capital Markets upped their price target on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the stock an “outperform” rating in a research note on Thursday, December 4th. Morgan Stanley raised their price objective on shares of Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the company an “equal weight” rating in a research note on Monday, February 2nd. Finally, Royal Bank Of Canada upped their target price on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a “sector perform” rating in a research report on Wednesday, October 29th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $793.81.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.